Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
08/2005
08/04/2005WO2005071098A1 Method of screening substance improving lipid metabolism
08/04/2005WO2005071084A1 Construction of gutted recombinant adenovirus effectively expressing antibodies comprising human constant region and uses thereof
08/04/2005WO2005070902A1 Therapeutic agents ii
08/04/2005WO2005070442A1 A synergistic composition for treating hyperlipidemia
08/04/2005WO2005070413A1 Retinoic acid-containing remedy for diabetes
08/04/2005WO2004007457A3 Substituted benzylamine derivatives and methods of use
08/04/2005US20050172359 Using expression vector comprising phaseolin promoter to transfer and express plasma lipoprotein in seeds
08/04/2005US20050171346 Proteases, kinases enzyme inhibitors; cardiovascular disorders; central nervous system disorders; antiinflammatrory agents; bone disorders; infections
08/04/2005US20050171204 2S)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid; treating lipid disorders (dyslipidemias), insulin resistance
08/04/2005US20050171196 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
08/04/2005US20050171178 Exo-1-methyl-1H-imidazole-4-sulfonic acid {3-[6-ethyl-3-(2-hydroxy-indan-2-ylmethyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-phenyl}-amide; opioid receptors (mu, kappa and delta) antagonists; not substrate of the variable enzyme CYP2D6; addiction to an opiates, alcohol; obesity
08/04/2005US20050171174 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/04/2005US20050171158 1-(sulfonylaminomethylcarbonyl)-4-cyclohexylpiperidine compounds such as N-[1-(R)-(4-chlorobenzyl)-2-(4-cyclohexyl-4-[1,2,4]triazol-1-ylmethyl-piperidin-1-yl)-2-oxo-ethyl]-methanesulfonamide; various diseases and disorders such as weight control, eating disorders
08/04/2005US20050171151 Administering retinoic acid receptors (RAR) antagonist or an RAR inverse agonist for therapy of hyperlipidemia in mammal
08/04/2005US20050171149 antioxidant properties and peroxisome proliferator activated receptors (PPAR) alpha and PPAR gamma activator properties; cardiovascular diseases, syndrome X, restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms, neurodegenerative, and skin disorders
08/04/2005US20050171129 Polycyclic guanine derivative phosphodiesterase V inhibitors
08/04/2005US20050171128 Pyrrolo[2,3-d]pyrimidine compounds
08/04/2005US20050171118 Central nervous system, gastrointestinal and psycological disorders; such as 3-(4-chlorobenzenesulfonyl)-2-methyl-7-piperazin-1-yl-1H-indole; synthesis
08/04/2005US20050171111 E.g., 4-[[5-[[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-6-quinolinyl]hydroxymethyl]-1H-imidazol-1-yl]methyl]-benzonitrile; prevents the membrane attachment of p21ras and blocks the aberrant growth of ras-transformed tumors
08/04/2005US20050171104 Novel thyroid receptor ligands
08/04/2005US20050171101 Neurodegenerative diseases; diseases ascribed by NMDA- and NO-induced neurotoxicity ; ischemia; antiinflammatory; anticancer; antidiabetic; 2-{3-[4-Phenyl-3,6-dihydro-1(2H)-pyridyl]propyl}-6(5H)-phenanthridinone
08/04/2005US20050171098 MCH antagonists and their use in the treatment of obesity
08/04/2005US20050171096 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
08/04/2005US20050171094 Pyrrolopyrimidine derivatives
08/04/2005US20050171092 Chemical compounds
08/04/2005US20050171075 Substitued 19-nor-cholestenes; antineoplastic agents, wound healing agents, antiinflammatory agents; autoimmune diseases, transplant rejection inhibition, hyperplasia, graft versus host disease; increased cell growth modulation and differentiation, low calcemic activity
08/04/2005US20050171070 Stable salts of o-acetylsalicylic acid containing basic amino acids II
08/04/2005US20050171068 Novel 4-dedimethylaminotetracycline derivatives
08/04/2005US20050171009 by addition of surfactants such as nonionic surfactants of the (poly)ethoxylated fatty acid type; storage stability to hydrophobic aggregation nuclei for several months under temperature stress
08/04/2005US20050170440 Treatment and diagnosis of insulin-resistant states
08/04/2005US20050170010 Pharmaceutical Antidiabetic Composition
08/04/2005US20050169999 beta -carotene was dissolved in n-isobutyl or isobutyl acetate, hot solvent phase was dispersed in a modified water starch solution, evaporation of solvent, drying the dispersion; obtained beta -carotene used as colorant, for food, beverages, nutrition fortified food and pharmaceuticals
08/04/2005US20050169988 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
08/04/2005US20050169983 Chewable soft capsule
08/04/2005US20050169982 Topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms; seizures, obesity, neuropathic pain, affective disorders, tobacco cessation, chronic fatigue syndrome, drug addiction; highly soluble, bioavailability
08/04/2005US20050169976 Insulin administration apparatus
08/04/2005DE10246434B4 Carboxyalkoxy-substituierte Acyl-carboxyphenyl-harnstoffderivate und ihre Verwendung als Arzneimittel Carboxyalkoxy-substituted acyl-carboxyphenyl urea derivatives and their use as medicaments
08/04/2005CA2554233A1 Substituted n-cyclohexyl imidazolinones having an mch-modulatory effect
08/04/2005CA2554138A1 Aryl substituted heterocycles, method for production and use thereof as medicaments
08/04/2005CA2553649A1 Compounds for the sustained reduction of body weight
08/04/2005CA2553405A1 Antidiabetic oxazolidinediones and thiazolidinediones
08/04/2005CA2553207A1 Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
08/03/2005EP1560025A2 Specific markers for diabetes
08/03/2005EP1559726A2 Growth differentiation factor-10
08/03/2005EP1559724A1 Glp-1 derivatives and transmicosal absorption preparations thereof
08/03/2005EP1559710A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
08/03/2005EP1559703A1 A natural compound useful for treating diabetes, its preparation and use
08/03/2005EP1559428A1 Receptor regulator
08/03/2005EP1559424A2 The use of inhibitors of the renin-angiotensin system
08/03/2005EP1559422A1 Receptor function controlling agent
08/03/2005EP1558615A1 Purine compounds and use thereof as cannabinoid receptor ligands
08/03/2005EP1558612A1 Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same
08/03/2005EP1558590A1 Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof
08/03/2005EP1558578A1 Novel alkyne compounds having an mch antagonistic effect and medicaments containing these compounds
08/03/2005EP1558572A2 Novel compounds and their use as prar-modulators
08/03/2005EP1558571A1 Novel compounds useful in treating ppar mediated diseases
08/03/2005EP1558567A1 Novel amide compounds with mch antagonistic effect and medicaments comprising said compounds
08/03/2005EP1558566A1 Novel phenylnaphthalene derivatives, method for production thereof and pharmaceutical compositions comprising the same
08/03/2005EP1558252A2 Substituted furo 2,3-b] pyridine derivatives
08/03/2005EP1558244A2 Novel nutraceutical compositions comprising epigallocatechin gallate
08/03/2005EP1558240A2 Hypoestoxides, derivatives and agonists thereof for use in the treatment and prophylaxis of hyperlipidemia
08/03/2005EP1558237A2 Improved glycemic control for prediabetes and/or diabetes type ii using docosahexaenoic acid
08/03/2005EP1558220A1 Oral compositions for treatment of diseases
08/03/2005EP1558199A2 Therapeutic combination of carnitine and antioxidant polyphenols
08/03/2005EP1429750A4 Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
08/03/2005EP1330455B1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
08/03/2005EP1330166B1 Food grade transglutaminase inhibitor and uses thereof
08/03/2005EP1287017B1 2-substituted pregna-1,3,5(10)-triene and chola-1,3,5(10)-triene derivatives and their biological activity
08/03/2005EP1283708B1 Use of biguanide derivatives for making a medicine having a wound healing effect
08/03/2005EP1228059B1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof
08/03/2005EP1175433B1 Androgen glycosides and androgenic activity thereof
08/03/2005EP1142890B1 Aminopyrazole derivatives
08/03/2005EP1140173B1 Vascular endothelial cell growth factor antagonists and uses thereof
08/03/2005EP1131344B1 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof
08/03/2005EP0988108B1 superporous hydrogel composites having fast swelling, high mechanical strenght, and superabsorbent properties
08/03/2005EP0946550B1 PREPARATION OF [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-CHLORO-2-THIENYL)METHYL]PROPYL]AMINO]-3H-IMIDAZO[4,5-b]PYRIDIN-3-yl]-N-ETHYL-2,3-DIHYDROXYCYCLOPENTANECARBOXAMIDE
08/03/2005EP0851925B1 Human growth hormone variants
08/03/2005EP0832651B1 Use of fructooligosaccharides (FOS) for lowering blood lipid peroxide level
08/03/2005EP0825259B1 Monoclonal antibody reactive with human-origin cetp and method of quantifying human-origin cetp
08/03/2005EP0707596B1 Polymer-peptide conjugates
08/03/2005CN1649897A FALP proteins
08/03/2005CN1649895A Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
08/03/2005CN1649871A Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6, 7, 8, 9-tetrahydropydimido[1, 2-a]pyrimidin-4-one derivatives
08/03/2005CN1649870A 7-aryl-3, 9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
08/03/2005CN1649869A Azaindoles as inhibitors of c-Jun N-terminal kinases
08/03/2005CN1649867A Novel 1, 2, 3-substituted indolizine derivatives, inhibitors of FGFs, method for making same and pharmaceutical compositions containing same
08/03/2005CN1649859A Substituted phenylacetamides and their use as glucokinase activators
08/03/2005CN1649857A Hydroxamic acid derivatives
08/03/2005CN1649855A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
08/03/2005CN1649849A Tachykinin receptor antagonists
08/03/2005CN1649848A Fused pyrimidines derivatives as antagonists of the corticotropin releasing factor (CRF)
08/03/2005CN1649843A Novel chalcone derivatives and uses thereof
08/03/2005CN1649841A Piperidine derivative compound and drug containing the same compound as active ingredient
08/03/2005CN1649840A Non-peptidic BRS-3 agonists
08/03/2005CN1649834A Novel propionic acid derivative
08/03/2005CN1649820A Compounds that modulate PPAR activity and methods for their preparation
08/03/2005CN1649819A Novel thyroid receptor ligands
08/03/2005CN1649644A Compositions and methods for treatment of body weight conditions with milk minerals and casein fractions
08/03/2005CN1649624A Use of TNF alpha antibodies and another drug
08/03/2005CN1649617A Remedies for liver diseases, hyperlipemia and diabetes
1 ... 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 ... 1298